CML: Asciminib Bests Standard TKIs as Frontline Therapy
Asciminib demonstrated efficacy vs standard-of-care frontline TKIs in newly diagnosed patients with CML.
Source: medscape.com
Jorgee Cortes News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Jorgee Cortes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Jorgee Cortes Today - Breaking & Trending Today
Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a peer-reviewed publication in Leukemia & Lymphoma on data from an analysis of the...
Source: prnewswire.com
Rigel Announces Poster Presentations at the 65th American Society of Hematology Annual Meeting and Exposition
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the upcoming presentation of four posters highlighting data from their commercial...
Source: prnewswire.com
Cancer Researchers and Student Athletes Are "Here to Win" for Innovation, Discovery, and Hope
Building an innovative cancer research project takes time, creativity, and most importantly, a team of scientists working together on why a new way to treat cancer or keep the cancer from spreading to other parts of the body.
Source: onclive.com
Rigel Announces Presentation of Data from Analysis of REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced promising data from an analysis of the Phase 2 study evaluating REZLIDHIA®...
Source: prnewswire.com